- Home
- CLPT vs ABEO Comparison
CLPT vs ABEO Comparison
Compare CLPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | ABEO |
|---|---|---|
| Founded | 1998 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.3M | 399.5M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CLPT | ABEO |
|---|---|---|
| Price | $14.12 | $6.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $20.00 | $20.00 |
| AVG Volume (30 Days) | 580.5K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | $2,998,000.00 |
| Revenue This Year | $45.67 | $1,024.31 |
| Revenue Next Year | $19.51 | $145.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.78 | ★ 258.18 |
| 52 Week Low | $8.27 | $4.00 |
| 52 Week High | $30.10 | $7.54 |
Technical Indicators
Market Signals| Indicator | CLPT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 43.56 |
| Support Level | $13.38 | $4.94 |
| Resistance Level | $15.09 | $7.36 |
| Average True Range (ATR) | 0.79 | 0.38 |
| MACD | -0.46 | -0.11 |
| Stochastic Oscillator | 7.03 | 0.55 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.